CTNM
Contineum Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.44
+5.08%Oct 12, 2026, 16:59 UTC
Contineum Therapeutics, Inc. shares plunged Monday after mixed Phase 3 results for a competing lung disease drug.
Source:Sep 14, 2026, 20:38 UTC
Contineum Therapeutics announced that an experimental depression drug developed with Johnson & Johnson failed to meet the main goal of a mid-stage clinical trial.
Jun 30, 2026, 20:05 UTC
Contineum Therapeutics published a manuscript in the Journal of Medicinal Chemistry describing the discovery of its potential best-in-class LPAR1 antagonist PIPE-791.
Source: